HilleVax (NASDAQ:HLVX) Stock Rating Lowered by SVB Leerink

HilleVax (NASDAQ:HLVXGet Free Report) was downgraded by SVB Leerink from an “outperform” rating to a “market perform” rating in a research note issued to investors on Tuesday, MarketBeat.com reports. They currently have a $2.00 target price on the stock, down from their previous target price of $28.00. SVB Leerink’s price objective indicates a potential upside of 22.70% from the company’s previous close.

A number of other research firms have also weighed in on HLVX. Stifel Nicolaus lowered HilleVax from a “buy” rating to a “hold” rating and cut their price objective for the stock from $34.00 to $3.00 in a research report on Tuesday. Guggenheim lowered HilleVax from a “buy” rating to a “neutral” rating in a research report on Monday. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $5.00 price objective (down previously from $24.00) on shares of HilleVax in a research report on Monday. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $2.00 price objective (down previously from $28.00) on shares of HilleVax in a research report on Tuesday. Six equities research analysts have rated the stock with a hold rating, According to MarketBeat.com, HilleVax has an average rating of “Hold” and an average price target of $9.20.

View Our Latest Stock Analysis on HLVX

HilleVax Trading Down 3.6 %

HLVX opened at $1.63 on Tuesday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 10.92 and a current ratio of 10.92. The business’s 50 day moving average price is $13.04 and its 200 day moving average price is $14.59. HilleVax has a one year low of $1.55 and a one year high of $20.22. The stock has a market capitalization of $81.04 million, a PE ratio of -0.49 and a beta of 0.78.

HilleVax (NASDAQ:HLVXGet Free Report) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.13). As a group, equities research analysts expect that HilleVax will post -3.14 EPS for the current year.

Insider Activity at HilleVax

In related news, Director Aditya Kohli sold 6,000 shares of the firm’s stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $14.73, for a total value of $88,380.00. Following the completion of the sale, the director now owns 764,878 shares in the company, valued at $11,266,652.94. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders sold a total of 12,898 shares of company stock worth $193,766 over the last 90 days. Company insiders own 71.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. EntryPoint Capital LLC purchased a new position in shares of HilleVax during the 1st quarter worth approximately $80,000. SG Americas Securities LLC purchased a new position in shares of HilleVax during the 4th quarter worth approximately $139,000. Tidal Investments LLC purchased a new position in shares of HilleVax during the 1st quarter worth approximately $207,000. abrdn plc purchased a new position in shares of HilleVax during the 4th quarter worth approximately $433,000. Finally, Swiss National Bank increased its stake in shares of HilleVax by 22.4% during the 4th quarter. Swiss National Bank now owns 38,200 shares of the company’s stock worth $613,000 after purchasing an additional 7,000 shares in the last quarter. 86.42% of the stock is owned by hedge funds and other institutional investors.

HilleVax Company Profile

(Get Free Report)

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.

Featured Articles

Analyst Recommendations for HilleVax (NASDAQ:HLVX)

Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with MarketBeat.com's FREE daily email newsletter.